ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) Net margin
ResMed Inc.'s net margin over the twelve months to 30 June 2026 was 26.9%. Over the past ten years it has ranged from 13.5% (fiscal 2018) to 27.2% (fiscal 2025); the current reading is higher than 92% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2026 | 26.9% | (0.28) |
| FY2025 | 27.2% | 5.43 |
| FY2024 | 21.8% | 0.54 |
| FY2023 | 21.3% | (0.53) |
| FY2022 | 21.8% | 6.94 |
| FY2021 | 14.8% | (6.18) |
| FY2020 | 21.0% | 5.50 |
| FY2019 | 15.5% | 2.03 |
| FY2018 | 13.5% | (3.07) |
| FY2017 | 16.6% | (2.61) |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 26.2% | (1.66) |
| Mar 2026 | 27.9% | 0.27 |
| Dec 2025 | 27.6% | 1.49 |
| Sep 2025 | 26.1% | (2.07) |
| 42 more quarters | Free account |
Against its own ten years
Low 13.5%
High 27.2%
Ten-year median
21.0%
Current reading's percentile
92
Net margin against peers
| Company | Net margin |
|---|---|
| RMD ResMed Inc. | 26.9% |
| SOLV Solventum Corporation compare | 17.3% |
| WST West Pharmaceutical Services, Inc. compare | 17.0% |
| COO The Cooper Companies, Inc. compare | 13.5% |
| ALC Alcon compare | 5.92% |
| RGEN Repligen Corporation compare | 5.29% |
| BDX Becton, Dickinson and Company compare | 4.20% |
| MDLN Medline Inc. compare | 2.37% |
| BAX Baxter International Inc. compare | −9.27% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement